Pharmaceutical Business Review

JUNE 16, 2023

Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries by 2030. It features crucial challenges that bar patients from gaining access to biosimilar medicines.

Biosimilars 59

Biosimilars Hospitals 59

European Pharmaceutical Review

JANUARY 31, 2025

Over 100 biosimilar medicines are approved for nearly 30 reference medicines, testimony to the rigour of the scientific standards leading to the European authorisation process. This makes biosimilar medicines highly relevant. A significant number of the possible biosimilar candidates are not blockbuster medicines.

Biosimilars 52

Biosimilars 52

Express Pharma

AUGUST 8, 2024

The National Health Commission of the People’s Republic of China launched a three-year “Weight Management Year” campaign in June 2024 as part of the broader Healthy China Action (2019-2030) and the Implementation Plan for the Prevention and Control of Obesity in Children and Adolescents.

Biosimilars 102

Biosimilars Diabetes 102

Express Pharma

MAY 29, 2024

These products are forecast to collectively generate over $32 billion by 2030, enabling AbbVie to financially rebound and continue its position as a leading immunology player, says GlobalData. billion due to the influx of biosimilars. billion by 2030. By 2030, the company is forecast to generate total revenue of $75.4

Biosimilars 101

Biosimilars 101

Big Molecule Watch

DECEMBER 16, 2024

UDENYCA , the only biosimilar to Amgens NEULASTA in the United States, is administered the day after chemotherapy treatment to decrease the incidence of infection by febrile neutropenia. The acquisition will expand Accord BioPharmas product portfolio and is expected to position the company for accelerated growth in the biosimilar industry.

Biosimilars 45

Biosimilars Chemotherapy 45

Pharma Leaders

JUNE 16, 2023

Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines. Dubbed Act4Biosimilars Action Plan, the new roadmap has been designed to boost the adoption of global biosimilar products by at least 30% points in more than 30 countries by 2030.

Biosimilars 52

Biosimilars Hospitals 52

Pharmaceutical Technology

JUNE 15, 2023

Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.

Biosimilars 52

Biosimilars Communication Pharmaceutical Companies Pharmaceutical Companies 52

Express Pharma

JANUARY 11, 2024

Canakinumb, set for a 2030 launch, is a biosimilar to the established Ilaris therapy. With Ilaris’ US patent expiring in 2024, this biosimilar is anticipated to enter the market and potentially diminish Ilaris’ share. Towards the forecast period’s end, two additional anti-inflammatory therapies are expected to debut.

Biosimilars 103

Biosimilars Compounding 103

Express Pharma

JULY 8, 2024

With the Indian pharmaceutical market projected to reach $130 billion by 2030, it is imperative that the budget supports the creation of a conducive ecosystem for cutting-edge research in pharmaceuticals. The industry is now at a pivotal moment, with an aspiration to grow to USD 120 billion by 2030.

Biosimilars 98

Biosimilars 98

European Pharmaceutical Review

JANUARY 10, 2023

Demand has risen rapidly in the last two years, driven by the increasingly bespoke solutions required for very sensitive new modalities like mRNA, the rapidly growing biologics pipeline and the need to increase access to biosimilars by lowering costs. The new zone will offer a central platform for partners to meet, connect and exchange ideas.

Packaging 96

Packaging Biosimilars 96

Pharmaceutical Technology

MAY 19, 2023

According to GlobalData’s recent Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update report, which identified 19 DMTs marketed for MS in the US, the average annual cost of therapy increased by 9% between 2020 and 2022. A similar trend of price increases was also seen for MS generics and biosimilars.

Biosimilars 98

Biosimilars 98

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. percent between 2022-2030. Based on the research by Roots Analysis, it is expected to hold 37 percent of the market share by 2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

Express Pharma

JULY 21, 2024

Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030. key expectations include; 1) Strong Focus on Innovations: research in the areas of cell and gene therapy, new molecular entities, biologics and biosimilars should be promoted.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 105

European Pharmaceutical Review

MAY 2, 2024

Recent developments in the biologic therapies sector include the authorisation of Pyzchiva ® (biosimilar ustekinumab) by the European Commission, and promising 12-month data for Roche’s subcutaneous injection of OCREVUS ® (ocrelizumab) for relapsing or primary progressive multiple sclerosis. Bn by 2030. Internet] Globe Newswire.

Biosimilars 105

Biosimilars Drug Development 105

Pharmaceutical Business Review

APRIL 17, 2024

It develops, manufactures and commercialises complex biotech and biosimilar drug products at its production facility in Nova Lima. million cases by 2030, according to the Diabetes Atlas of the International Diabetes Federation (IDF). “We and Europe for Peptides.

Diabetes 59

Diabetes Biosimilars 59

Express Pharma

OCTOBER 16, 2024

billion by 2030 (2). Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally. The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 per cent, is projected to reach $2.5 per cent, hitting $44.63

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

Express Pharma

NOVEMBER 18, 2024

India’s pharmaceutical industry is projected to reach $65 billion by 2024 and is expected to double to $130 billion by 2030. The event will include the Pharma Connect Congress, which will cover topics such as innovation in manufacturing, digital transformation in the pharma sector, and advancements in biosimilar research and manufacturing.

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Biosimilars 52

Express Pharma

MAY 8, 2025

And, since most of the future growth will come from biologics and biosimilars, how will India make its mark as a global biosimilar CDMO market? LMSs efforts are fully aligned with Lupins broader sustainability goals, including the carbon neutrality targets for 2030. How does LMS differentiate its offerings in the CDMO space?

Biosimilars 59

Biosimilars Packaging 59

Express Pharma

MAY 13, 2025

The report analyses 11 initiatives that have been specifically established to provide diabetes care for CYP, which are varyingly backed by major insulin producers Lilly, Novo Nordisk and Sanofi, as well as biosimilar insulin manufacturer Biocon. CYP’s access to long-term, affordable diabetes care remains a critical challenge.

Diabetes 88

Diabetes Biosimilars Compounding 88

FDA Law Blog: Biosimilars

JULY 10, 2024

As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030. Where technology is used to generate PGHD for clinical trials of other medical products, sponsors may need to provide WiFi and/or phones to study participants if what the patient has will not meet requirements to avoid excluding patients.

Diabetes 59

Diabetes 59

Express Pharma

NOVEMBER 26, 2024

With the Indian pharma market projected to grow to $ 130 billion by 2030 and $ 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. With exports nearing $27.84

Packaging 105

Packaging Biosimilars Pharmaceutical Manufacturing Dosage 105

FDA Law Blog: Biosimilars

DECEMBER 11, 2023

20, 2023) (“The lack of an equivalent IVD on the market is the primary reason labs develop LDTs.”) [7] PRIA. 8] FDA assumes that user fees will cover much of the increased costs.

Research Laboratories 69

Research Laboratories Documentation 69

Express Pharma

DECEMBER 18, 2024

The patent expiries of blockbuster biologics by 2025 present a significant growth avenue in the global biosimilars market. Indian pharma market is expected to move up to USD 120-130 Billion by 2030 from current size of USD 58 Billion.

Biosimilars 98

Biosimilars Vaccines 98

Express Pharma

DECEMBER 20, 2024

At the same time, Indias growing focus on tapping the $36 billion global biosimilars market highlights the need for real estate infrastructure that can support advanced manufacturing capabilities. This tech-driven evolution has been mirrored in the demand for state-of-the-art research and development (R&D) facilities and production hubs.

Biosimilars 103

Biosimilars Vaccines 103

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Express Pharma

JULY 15, 2024

With the Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, new molecular entities, biologics and biosimilars.

Medical Records 105

Medical Records Biosimilars Pharmaceutical Companies Pharmaceutical Companies 105

Express Pharma

JANUARY 12, 2024

With the Indian Pharma sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, biologics and biosimilars apart from the already strong generic and vaccine manufacturing sectors of the country.

Biosimilars 105

Biosimilars Vaccines 105

Express Pharma

JULY 10, 2024

Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. billion.”

Vaccines 96

Vaccines Drug Development Process Improvement Biosimilars 96

PharmaShots

APRIL 3, 2023

of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The authorization incl. multiple indications such as RA & Crohn's disease Hyrimoz was originally approved by the EC in 2018 with a concentration of 50mg/mL. 3 ADCs: Adcetris, Padcev & Tivdak.

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

pharmaphorum

NOVEMBER 10, 2022

We can talk all the time, Montserrat said, but now is the time for action: early diagnosis, access to the best treatments, innovation, in addition to protection of intellectual property (IP), and after that biosimilars and generics. With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity.

Vaccines 97

Vaccines Biosimilars Labelling Pharmaceutical Companies 97

Pharmaceutical Business Review

DECEMBER 26, 2024

We are confident that this partnership supports our efforts to manufacture and localise biosimilar products in the region and strengthen our market leading position in line with our strategy. This also stands as a commitment from our side to support the 2030 vision ofSaudi Arabiathrough localising biopharmaceutical products in the Kingdom.”

Biosimilars 52

Biosimilars Immunity Immunization Pharmaceutical Companies 52

Express Pharma

JANUARY 23, 2025

Edited excerpts Dr Patankar, there is a $75 billion biosimilars opportunity that is opening up due to the many biologics going off patent from 2022 to 2030. How do biosimilar companies in India ensure that they can leverage their strengths and maximise their opportunities during this period? So we need to keep that in mind.

Biosimilars 111

Biosimilars 111

Express Pharma

FEBRUARY 5, 2025

Looming patent expiries Patent expirations have been a significant opportunity for the Indian pharma space that is dominated by generics and biosimilars manufacturing. This trend is likely to continue as these companies continue to build a portfolio of branded specialty products and biosimilars.

Biosimilars 89

Biosimilars Drug Development Vaccines 89

Express Pharma

FEBRUARY 10, 2025

Indias pharma exports are projected to grow from $27 billion in 2023 to $65 billion by 2030 and could reach an estimated $350 billion by 2047. Innovation, including the shift towards specialty generics, biosimilars, and novel products, will be the key to Indias pharmaceutical future. Indian biosimilar exports, valued at ~$0.8

Biosimilars 98

Biosimilars Vaccines 98

Express Pharma

MARCH 21, 2025

As Hyderabad aims to expand its life sciences sector from $100 billion to $250 billion by 2030, adopting an integrated research campus model could be the key to achieving this growth.

Vaccines 65

Vaccines Biosimilars Drug Development 65

Express Pharma

JANUARY 3, 2025

While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.

Biosimilars 105

Biosimilars Vaccines Diabetes 105